ZKB/CALL/MODERNA/150/0.025/27.01.25 | Real-time Bid/Ask 11:53:03 23/05/2024 BST | ||
| 0.83 CHF / 0.84 CHF | +4.37% |
|
| Current month | +207.69% | ||
| 1 month | +300.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 0.8 | +56.86% |
| 21/05/24 | 0.51 | +24.39% |
| 16/05/24 | 0.41 | +13.89% |
| 15/05/24 | 0.36 | -5.26% |
| 14/05/24 | 0.38 | +22.58% |
Delayed Quote Swiss Exchange
Last update May 22, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | ZKB |
| MRNK8Z | |
| ISIN | CH1305130143 |
| Date issued | 09/01/2024 |
| Strike | 150 $ |
| Maturity | 27/01/2025 (250 Days) |
| Parity | 40 : 1 |
| Emission price | 0.45 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.8 CHF |
|---|---|
| Lowest since issue | 0.13 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.19% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- MRNK8Z Warrant
